STAT

The DEA wanted new suppliers of marijuana for research. Two years later, nothing has changed

Two years ago, the Trump administration said it would consider licensing new suppliers of marijuana grown to study its potential medical uses and risks. Scientists and lawmakers are still waiting.
Source: AP Photo/Robert Jordan

Two years ago, federal drug authorities said they would consider licensing new suppliers of marijuana grown for scientific purposes, a move seen as an acknowledgment of the need for additional rigorous research into potential medical uses and risks of cannabis and its components.

Hope you weren’t holding your breath.

The Drug Enforcement Administration still has not granted additional licenses for a after it announced it was open to approving one. The agency told STAT it had stopped accepting new applications and referred additional questions about licenses to the Justice Department, which did not return requests for comment.

Stai leggendo un'anteprima, registrati per continuare a leggere.

Altro da STAT

STAT1 min lettiMedical
STAT+: Pharmalittle: U.S. Considers Giving Half-doses Of Moderna Vaccine; Americans May Not Get AstraZeneca Shot Until April
The U.S. government is considering giving some people half the dose of the Moderna Covid-19 vaccine in order to speed vaccinations.
STAT1 min letti
STAT+: Pharmalittle: Hospitals Grapple With Extra Dose Of Pfizer Vaccine; FDA Panel Meets To Review Moderna Vaccine
With the Covid-19 vaccine in short supply, hospital pharmacists found themselves throwing away one in every six doses of the first vaccines distributed this week in the U.S.
STAT1 min lettiMedical
STAT+: Pharmalittle: Novavax Faces Raw-materials Shortages For Covid-19 Shot; India Curbs Vaccine Exports
Novavax is delaying signing a contract to supply its Covid-19 vaccine to the European Union because the company is struggling to source raw materials.